The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Spectrum and implications of activating BRAF alterations in advanced prostate cancer (aPC).
 
Alex Chehrazi-Raffle
No Relationships to Disclose
 
Hanna Tukachinsky
Stock and Other Ownership Interests - Foundation Medicine; Roche
 
Alexa Betzig Schrock
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine; Roche
 
Justin Hwang
Research Funding - Astrin Biosciences
 
Zeynep Busra Zengin
No Relationships to Disclose
 
Luis A Meza
No Relationships to Disclose
 
Neal Shiv Chawla
No Relationships to Disclose
 
Hedyeh Ebrahimi
No Relationships to Disclose
 
Ameish Govindarajan
No Relationships to Disclose
 
Daniela V. Castro
No Relationships to Disclose
 
Adam Rock
No Relationships to Disclose
 
Abhishek Tripathi
Honoraria - Cardinal Health; Targeted Oncology; Urology times
Consulting or Advisory Role - Deka Biosciences; EMD Serono; Exelixis; Exelixis; Foundation Medicine; Genzyme; Pfizer; Seagen
Research Funding - Aravive (Inst); Bayer (Inst); Bayer (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Exact Sciences (Inst); Exelixis (Inst); Pfizer (Inst); WindMIL (Inst)
 
Tanya B. Dorff
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Exelixis; Janssen Oncology; Pfizer; Seagen
Research Funding - Pfizer (Inst)
 
Sumanta Monty Pal
Research Funding - Allogene Therapeutics (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - crispr therapeutics; Roche
 
Geoffrey R. Oxnard
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
 
Emmanuel S. Antonarakis
Honoraria - AIkido Pharma; Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Celgene; Clovis Oncology; Constellation Pharmaceuticals; Curium Pharma; Dendreon; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Orion; Sanofi; Tempus
Consulting or Advisory Role - AIkido Pharma; Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clovis Oncology; Constellation Pharmaceuticals; Curium Pharma; Dendreon; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Orion; Sanofi; Tempus
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Celgene; Clovis Oncology; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi